Why Clearmind Stock Is Climbing Higher Tuesday

Clearmind Medicine Inc CMND shares are trading higher Tuesday after the company announced results in its cocaine addiction treatment.

What Happened: Clearmind said it achieved positive results in addiction treatment testing of the company's innovative psychedelic molecule MEAI. 

Clearmind filed a patent application related to cocaine addiction following the company's collaboration testing with SciSparc's CannAmide.

"Our unique psychedelic compound has shown remarkable results in pre-clinical trials for cocaine addiction," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

"These promising results from our MEAI-based treatment offer a potential paradigm shift in how we approach the complex challenge of cocaine addiction, an addiction for which no dedicated treatment has yet been developed."

Clearmind is a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems.

See Also: What's Going On With Sidus Space Stock Today?

CMND Price Action: Clearmind shares were up 66.9% at $6.42 at the time of publication, according to Benzinga Pro.

Photo: Pexels from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!